We measured the CVC colonization and infection incidence for PVP-IA (Betadine alcoolique ® ) and for CBA (Biseptine ® ) during two successive 1-year periods of routine surveillance (REA RAISIN network). A questionnaire on the ease of CBA use was administered. Consumption data were obtained from the hospital pharmacy. Results: The study included 806 CVC (CBA period: 371). Upon switching from PVP-IA to CBA, we recorded a significant reduction in colonization incidence/100 catheter days (1.12 vs. 1.55, p = 0.041), nonsignificant differences concerning CVC-related infection incidence/100 catheter days (0.28 vs. 0.26, p = 0.426), and a nonsignificant reduction in CVC-related bacteremia/100 catheter days (0.14 vs. 0.30, p = 0.052). PVP-IA users were at significantly higher risk of CVC colonization or infection based on a multivariate Cox model analysis (relative risk [95% CI]: 1.48 [1.01-2.15], p = 0.043). The main drawbacks of CBA use were its low cleansing activity and its colorless solution. No cost advantage was found. Conclusions: Our field study revealed no major clinical advantage of CBA use in CVC infection and no cost advantage in addition to limited ease of use.
Introduction
The use of central venous catheters (CVC) in intensive care units is widespread but is associated with potentially serious infections. Prevention of these infections is addressed in guidelines that are regularly updated as new studies are published [1, 2] .
For catheter insertion and care, different antiseptic formulations that involve the use of povidone-iodine or chlorhexidine are used most frequently. The povidone-iodine solution, widely used in France, was available first in aqueous solution and more recently as an ethanol-based solution (Betadine alcoolique ® ). Parienti et al. used the PVP-IA and found it to be more effective than the aqueous solution [3] . Currently, PVP-IA is considered to be the preferred product for CVC care. Chlorhexidine is more common than povidone-iodine in other countries, is available at different concentrations (0.5-4%) and can be used alone or in association with other products (alcohol or others). Historically, several studies have shown that for catheter insertion and care, chlorhexidine seems to have a better antiseptic effect than povidone-iodine. In a metaanalysis, Chaiyakunapruk et al. [4] concluded than chlorhexidine use is associated with a reduction of catheter-related bloodstream infection and a consistent reduction of costs [5] , but all 8 studies included in the meta-analysis compared an aqueous solution of povidone-iodine to alcohol based or aqueous chlorhexidine solutions. The same reference solution was used by Humar et al. in a study on CVC-related infections [6] and by Langgartner et al. in a study on CVC colonization [7] . A large number of international studies have explored different chlorhexidine antisepsis (with or without alcohol or at different concentrations), but the reference solution was an aqueous solution of povidone-iodine in each case [8] [9] [10] . More recently, Mimoz et al. compared a recently developed chlorhexidine-based antiseptic (CBA) solution (0.25% chlorhexidine gluconate, 0.025% benzalkonium chloride and 4% benzyl alcohol, Biseptine ® ) to PVP-IA and found CBA to be more effective [11] .
Our unit has used PVP-IA since 2006. However, because many intensive care units in France chose chlorhexidine, we decided to conduct a field test on PVP-IA and this new CBA solution that was tested by Mimoz et al. to determine whether it would be worthwhile, in terms of effectiveness, ease of use, and cost, to switch to CBA for CVC-related care.
Materials and methods

Design and setting
This prospective longitudinal field study was conducted within our routine surveillance program for hospital-acquired infections (the REA RAISIN surveillance network) [12] . This network is the French organization for the nosocomial infection surveillance network of the European Centre for Disease Prevention and Control. It includes each patient hospitalized in an intensive care unit; for each patient, the following data are collected, using standardized definitions: infectious risk, exposure and acquired infections.
Patients and intervention
All patients who spent at least 2 days in our medical ICU between January 2007 and June 2009 and in whom at least one CVC was inserted were included in the study. The CVCs were nontunneled; single-, double-or triple-lumen; without a cuff; and without antimicrobial impregnation. We used PVP-IA until June 1, 2008, and thereafter recommended the use of CBA (Biseptine ® ). Biseptine ® is an aqueous solution containing 0.25% CHG, 0.025% benzalkonium chloride, and 4% benzyl alcohol (Bayer Santé Familiale, Gaillard, France). The protocols for CVC insertion and care were as follows: (i) cleaning with a PVP-I scrub (Betadine scrub ® , Meda Pharma, Paris, France), rinsing with sterile water, drying with a swab, and the application of PVP-IA (Betadine alcoolique ® , Meda Pharma, Paris, France) and (ii) cleaning with CBA, drying with a swab, and a second CBA application. All staff received instruction in the CBA protocol. All CVCs removed in the unit were sampled and tested by the same method. For patients discharged from the hospital with a CVC, the duration of CVC use included only use in the ICU. Povidone was used in the units for many purposes, such as urinary catheters and tracheal suction in cases that required intubation. It could not be excluded from the unit during the test period, but it was never used for CVC, as confirmed by two investigators.
Data collection
ICU physicians collected data on patient age, gender, Simplified Acute Physiology Score (SAPS II), immunodeficiencies, and invasive procedures (including their duration). They recorded the date of CVC insertion and removal as well as the site of CVC insertion.
CVC tip colonization was assessed using a semiquantitative culture method. A CVC-related infection was defined as the (1) presence of local signs of infection (pus, inflammation or pain) or of general signs of infection together with (2) evidence for CVC colonization or a ≥5-fold higher bacterial count for the CVC tip than for a paired quantitative peripheral blood culture, with (3) spontaneous resolution within 48 h of CVC removal. CVC-related bacteremia was defined as bacteremia onset 48 h before or after CVC removal, as evidenced by at least one positive blood culture from a peripheral blood sample containing a microorganism that was also found (1) in a paired quantitative blood culture, (2) in a positive culture from the insertion site or (3) in CVC tip colonization.
Outcome measures
Product efficacy was evaluated by determining CVC colonization, CVC-related infection and CVCrelated bacteremia rates. A univariate analysis was performed to compare both periods.
The comparison between PVP-IA and CBA could be biased by confounding factors, such as disease severity (SAPS II), duration of CVC use, exposure to other factors, and patients with immunodeficiency.
In an effort to test the specific effect of antisepsis, multivariate analysis was performed. To obtain better statistical power, the survival without any evidence of CVC infections (colonization, infection or bacteremia) was preferred to a separate analysis.
The ease of CBA use was evaluated by a questionnaire administered in May 2009 to all ICU staff members (physicians and nurses). Items covered bottle quality (size, ease of pouring and risk of spilling), cleansing capacity, presentation (colorless solution), protocol simplicity, tolerance, and maceration. Each item was evaluated on a 4-point Likert scale [13] (1 point if the response was ''completely disagree'', 2 points if it was ''rather disagree'', 3 points if it was ''rather agree'' and 4 points if it was ''completely agree'').
The costs incurred by CBA use compared with PVP-IA use were evaluated based on consumption figures provided by the hospital's pharmacy (last 7 months of 2007 for PVP-IA and last 7 months of 2008 for CBA). The ICU bed occupancy was similar for the two periods.
Statistics
Data were entered and analyzed by the Hygiene and Epidemiology Unit using Epi Info 2002 and SPSS V17 software. Standard statistical tests were used: Fisher's exact test and Pearson's chi-squared test for more than 2 situations were used for the comparison of percentages; nonparametric tests (Mann-Whitney U-test) were used for numerical data, many being nonnormally distributed, and the Z test was used for incidence rate comparisons.
For multivariate analysis, a Cox model was used for the comparison of survival of CVC without an infection-related problem. Each factor related to infectious risk in univariate analysis and interactions were included in the model.
Results
Patient and CVC characteristics
The study included 640 patients, 292 (45.6%) of whom were evaluated during the period of CBA use. A total of 806 CVCs were inserted (1.3/patient) for a total of 8567 days. Patient and CVC characteristics are given in Table 1 . During the period of CBA use, the included patients were significantly younger (p = 0.047) and heavier (p = 0.005); the rate of CVC insertion by the femoral route was significantly higher (p < 0.001), and the mean duration of CVC use in the ICU was significantly longer (p = 0.007).
Colonization and infection rates
Colonization and infection rates are compared in Table 2 for the two periods. During CBA use, the incidence of CVC colonization per 1000 catheter days, but not the overall incidence of CVC colonization, was significantly lower than during PVP-IA use (p = 0.041). Both the overall incidence of infection and the incidence per 1000 catheter days were higher but not significantly so. The overall incidence of CVC-related bacteremia and the incidence per 1000 catheter days were lower. The latter reached borderline significance (1.4 vs. 3.0, p = 0.052). The incidence of CVC colonization per 1000 catheter days was significantly higher for the femoral compared with the subclavian route (1.9 vs. 0.8, p < 0.001), but no significant difference was found between the two routes for the incidence per 1000 catheter days of CVC-related infection or bacteremia. Staphylococcus epidermidis was the main microorganism that was identified during these two periods.
A Cox multivariate analysis considered the differences in populations, CVCs, practices, and duration of CVC use. It also compared colonization and infection-free survival as functions of factors that could possibly be associated with the risk of CVC colonization or CVC-related infection, i.e., patient age and gender, SAPS II, immunodeficiencies, antibiotic treatment at admission, intubations (including duration), bladder catheterization (including duration), other hospital-acquired infections, and the CVC insertion site. Univariate and multivariate analysis are presented in Table 3 . for each study-period did not coincide. The first episode of infection or colonization occurred later during the CBA period (Fig. 1) . No factor was significant with regard to infections or bacteremia after the exclusion of colonization alone.
Ease of use
The response rate for the questionnaire on CBA use was 83.3% (35/42) (2 senior physicians, 3 residents, and 30 nurses). All 35 respondents had used the product for at least 2 months, and 25/35 had used it from the date of the protocol switch. Users liked the product's bottle, the ''no-stains-on-sheets'' aspect, and the need to use only one rather than several products (Table 4) . However, the cleansing effect of CBA for CVC care was considered to be limited (Likert score of 3.3/4). In addition, the fact that it was colorless was considered to be a major drawback for both CVC insertion and care (Likert score of 3.3/4 and 3.2/4 in response to ''absence of color bothersome'').
Cost
Because CBA cannot be used for disinfection of the mucosa, a PVP-I aqueous formulation suitable for the mucosa (Betadine dermique ® ) was used throughout the two study periods, together with a limited number of units of PVP-I scrub and PVP-IA. The comparison of antiseptic costs included all of the products that were consumed during 7-month periods with similar bed occupancy. The consumption of Betadine aqueous solution, which was used for additional CVC care, was similar between the periods. Biseptine consumption replaced the reduction in Betadine scrub and Betadine alcohol-based solution use (Table 5 ). Costs after the protocol switch from PVP-IA to CBA were slightly higher.
Discussion
Our study found that the period of CBA use was associated with a slightly lower risk of CVC colonization and bacteremia but was also associated with certain drawbacks. Many users considered its cleansing activity to be too limited and were bothered by the fact that the solution was colorless. The cost was no lower than that of PVP-IA use. It is unlikely that the lower CVC colonization risk observed during CBA use was due to guidance provided before switching the protocol for several reasons. During PVP-IA use (first study period), the CVC colonization and infection rates were already lower than those reported by Lorente et al. [14] and Parienti et al. [3] and close to those reported by Valles et al. [10] for chlorhexidine. Bacterial counts during this period were similar to those found by Ishizuka et al. [9] . In addition, our ICU staff, as well as the new arrivals, benefited from a continuous education program that includes training in CVC insertion and care.
In contrast to earlier studies, we found only a slight advantage of using CBA over PVP-IA. One explanation may be that we used alcohol-based and not aqueous PVP-I during the first study period. Most of the studies that have found CBA to be more effective have compared it to an aqueous PVP-I solution [5, 10, 11] . Parienti et al. [3] showed that alcoholbased PVP-I was better than aqueous PVP-I, and Mimoz et al. [15] , the only team to compare CBA to a PVP-IA, reported that CBA was more effective.
A limitation of our study as an in-depth product comparison is that it was a field study. A randomized trial is better at addressing all of the confounding factors. It is also possible that not all ICU staff complied with the protocol switch on the planned date. These differences might explain why the Mimoz et al. randomized trial recorded a significant difference in favor of CBA.
CBA users liked using the same product for cleansing and antisepsis but considered the fact that it was colorless to be a major drawback because the quality of antisepsis depends on ensuring full application [16, 17] . It is uncertain whether a switch from PVP-IA to CBA would be beneficial until the results are available for colored CBA products. A drawback of CBA is that it cannot be used for mucosa. Different products need to be stocked and managed. In conclusion, the best strategy for CVC antisepsis in an ICU is complex and must consider not only microbiological efficacy but also the ease of use and organizational aspects, especially because the small differences observed in efficacy have limited clinical significance.
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